Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more
Scilex Holding Company (SCLX) - Total Assets
Latest total assets as of September 2025: $275.88 Million USD
Based on the latest financial reports, Scilex Holding Company (SCLX) holds total assets worth $275.88 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Scilex Holding Company - Total Assets Trend (2020–2024)
This chart illustrates how Scilex Holding Company’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Scilex Holding Company - Asset Composition Analysis
Current Asset Composition (December 2024)
Scilex Holding Company's total assets of $275.88 Million consist of 44.7% current assets and 55.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.5% |
| Accounts Receivable | $26.44 Million | 28.5% |
| Inventory | $2.44 Million | 2.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $32.45 Million | 34.9% |
| Goodwill | $13.48 Million | 14.5% |
Asset Composition Trend (2020–2024)
This chart illustrates how Scilex Holding Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scilex Holding Company's current assets represent 44.7% of total assets in 2024, an increase from 27.5% in 2020.
- Cash Position: Cash and equivalents constituted 3.5% of total assets in 2024, down from 5.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, a decrease from 68.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 34.9% of total assets.
Scilex Holding Company Competitors by Total Assets
Key competitors of Scilex Holding Company based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Scilex Holding Company - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Scilex Holding Company generates 0.61x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Scilex Holding Company is currently not profitable relative to its asset base.
Scilex Holding Company - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.14 | 0.17 |
| Quick Ratio | 0.04 | 0.13 | -1.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-342.46 Million | $ -241.68 Million | $ -150.25K |
Scilex Holding Company - Advanced Valuation Insights
This section examines the relationship between Scilex Holding Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.85 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | -8.2% |
| Total Assets | $92.95 Million |
| Market Capitalization | $30.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scilex Holding Company's assets below their book value (0.33 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scilex Holding Company's assets decreased by 8.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scilex Holding Company (2020–2024)
The table below shows the annual total assets of Scilex Holding Company from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $92.95 Million | -8.25% |
| 2023-12-31 | $101.31 Million | +17.08% |
| 2022-12-31 | $86.53 Million | +11.03% |
| 2021-12-31 | $77.93 Million | -4.38% |
| 2020-12-31 | $81.50 Million | -- |